The latest announcement is out from CymaBay Therapeutics (CBAY). In a significant move for investors, a tender offer for all outstanding shares of a company commenced on February 23, 2024,
The latest announcement is out from CymaBay Therapeutics (CBAY). In a significant move for investors, a tender offer for all outstanding shares of a company commenced on February 23, 2024,
Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for approximately $4.3B in total equity value. “The addition of CymaBay’s investigational lead product
Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for $4.3B in total equity value. As a result of the completion of the
The latest announcement is out from CymaBay Therapeutics (CBAY). CymaBay Therapeutics, Inc. has made significant changes to its executive officers’ employment agreements, removing certain clauses related to severance payments and
CymaBay Therapeutics announced that the Marketing Authorization Application, MAA, for seladelpar, for the treatment of primary biliary cholangitis, PBC, including pruritus in adults without cirrhosis or with compensated cirrhosis who